We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


ACE Biosciences and Crucell Collaborate to Discover Antibody Therapies

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

ACE BioSciencesA/S and Crucell N.V. have entered a research and licensing agreement to discover antibody therapies to combat serious hospital-acquired infections, including those caused by antibiotic-resistant bacteria.
Under the terms of the agreement, Crucell gains exclusive rights to assay a number of proprietary protein targets that ACE BioSciences has isolated and extracted from the cell surface of relevant bacteria.

Crucell will develop antibodies opposite these targets and in-licence the most promising ones for use in its anti-infection product development programme.

ACE BioSciences will be eligible for royalty and milestone payments on any therapies derived from the collaboration. ACE BioSciences was advised by BioSciencemanagers Ltd.
Ms Ingelise Saunders, ACE BioSciences’ CEO commented, "We are delighted that a company of the stature and experience of Crucell should recognize the unique therapeutic potential of our protein targets in the fight against infection."

"This deal validates the quality of our proteomics expertise and underlines the potential of our work in this large and underserved therapeutic area. I am confident that this is the first of a number of deals which we will broker in the coming months."